LNP-Replicon RNA Oncolytic Vector for Local and Systemic Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments struggle to induce a robust anti-cancer immune response both locally at the tumor site and systemically against distal tumors, limiting their effectiveness in cancer therapy.
Innovation Solution
A synthetic oncolytic virus comprising a lipid nanoparticle and a self-amplifying replicon RNA encoding an IL-12 molecule is injected at a tumor site, which triggers immunogenic cell death and systemic immunity by recruiting immune cells and enhancing IL-12 expression, thereby targeting both local and distal tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional cancer treatments are used, then local tumor treatment is achieved, but systemic immunity against distal tumors is not induced
Solution Approach 1:
The patent combines local tumor-targeting capability with systemic immune activation by using a synthetic oncolytic virus that simultaneously achieves immunogenic cell death at the tumor site and releases immunomodulatory molecules (IL-12) that travel systemically to activate immunity against distal tumors. This merging of local and systemic effects resolves the contradiction between localized treatment and systemic protection.
Solution Approach 2:
The synthetic oncolytic virus acts as an intermediary carrier that delivers immunomodulatory molecules from the local tumor site to the systemic circulation. The virus particles transport IL-12 and other immunostimulatory agents, enabling the local treatment to have systemic consequences and induce broad anti-cancer immunity.
2Productivity
If synthetic oncolytic virus with IL-12 encoding is used, then synergistic anti-tumor immune response is induced, but virus design and composition complexity increases
Solution Approach 1:
The synthetic oncolytic virus is designed with multi-functionality: it serves as both an oncolytic agent (killing tumor cells) and an immunomodulatory delivery vehicle (expressing IL-12). By integrating multiple functions into a single viral platform, the patent achieves synergistic therapeutic efficacy without requiring separate treatments, thereby managing complexity through functional integration rather than multiple components.
Solution Approach 2:
The patent modifies specific parameters of the viral genome to include the IL-12 coding sequence in a subgenomic region, while maintaining the essential replicon RNA functionality. This targeted parameter change (adding specific genetic material without disrupting core viral functions) enables enhanced therapeutic efficacy while controlling the degree of complexity introduced.
3Duration of action of moving object
If self-amplifying replicon RNA is used, then sustained IL-12 expression is achieved, but manufacturing precision requirements increase
Solution Approach 1:
The self-amplifying replicon RNA utilizes the host cell's replication machinery to amplify itself and sustain IL-12 expression over time. The replicon RNA self-replicates without requiring external intervention, thereby achieving prolonged therapeutic effect. This self-service mechanism extends expression duration while relying on the host's natural replication fidelity, which manages the precision requirement.
Solution Approach 2:
The replicon RNA is designed with a subgenomic region containing the IL-12 coding sequence that is transcribed and expressed during the viral replication cycle. This preliminary incorporation of the therapeutic gene into the replicon structure ensures that IL-12 expression is built into the replication process itself, achieving sustained expression while establishing precise manufacturing requirements in advance.
Data Source
Figure 1A~1H
Figure 2A~2J
Figure 3A~3K
AI summary
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.